4.80

2.44% -0.12

After Hours: 4.89 0.09 +1.87%

Protara Therapeutics Inc (TARA)

Overview News Price History Option Chain Financials Discussions Forecast

Protara Therapeutics Inc stock is traded at $4.80, with a volume of 826.36K. It is down -2.44% in the last 24 hours and down -6.43% over the past month. Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

Previous Close:

$4.92

Open:

24h Volume:

826.36K

Relative Volume:

0.88

Market Cap:

$269.78M

Revenue:

Net Income/Loss:

$-57.44M

P/E Ratio:

-3.5925

EPS:

-1.3361

Net Cash Flow:

$-56.46M

1W Performance:

+10.60%

1M Performance:

-6.43%

6M Performance:

-35.18%

1Y Performance:

+53.35%

1-Day Range:

$4.62

$5.005

1-Week Range:

$4.41

$5.09

52-Week Range:

$2.77

$7.82

Protara Therapeutics Inc Stock (TARA) Company Profile

Name

Protara Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

646-844-0337

Address

345 PARK AVENUE SOUTH, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

TARA's Discussions on Twitter

Compare TARA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARA Protara Therapeutics Inc	4.80	276.52M	0	-57.44M	-56.46M	-1.3361
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-26	Initiated	JP Morgan	Overweight
Jan-07-26	Initiated	Piper Sandler	Overweight
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Mar-14-25	Initiated	Cantor Fitzgerald	Overweight
Jul-10-23	Resumed	Guggenheim	Buy
Jun-04-21	Initiated	H.C. Wainwright	Buy
Feb-17-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Cowen	Outperform
Jul-29-20	Initiated	Guggenheim	Buy

View All

Protara Therapeutics Inc Stock (TARA) Latest News

11:34 AM

TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, with key H2 catalysts - TradingView

11:34 AM

06:29 AM

[EFFECT] Protara Therapeutics, Inc. SEC Filing - Stock Titan

06:29 AM

May 23, 2026

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study - MSN

May 23, 2026

May 22, 2026

Piper Sandler initiates coverage of Protara Therapeutics (TARA) with overweight recommendation - MSN

May 22, 2026

May 21, 2026

Protara Therapeutics Inc stock (US87612E1064): analyst optimism contrasts with volatile share price - AD HOC NEWS

May 21, 2026

A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $24 to $28 - Moomoo

May 21, 2026

Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail

May 21, 2026

Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV) - The Globe and Mail

May 21, 2026

Piper Sandler Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $24 - Moomoo

May 21, 2026

What's Driving Protara's Recent Surge - Kavout

May 21, 2026

May 20, 2026